JP2025509969A - Ｅｒｋのピロール阻害剤の重水素化アナログ、その合成およびその中間体 - Google Patents

Ｅｒｋのピロール阻害剤の重水素化アナログ、その合成およびその中間体 Download PDF

Info

Publication number
JP2025509969A
JP2025509969A JP2024556148A JP2024556148A JP2025509969A JP 2025509969 A JP2025509969 A JP 2025509969A JP 2024556148 A JP2024556148 A JP 2024556148A JP 2024556148 A JP2024556148 A JP 2024556148A JP 2025509969 A JP2025509969 A JP 2025509969A
Authority
JP
Japan
Prior art keywords
compound
formula
pharmaceutical composition
deuterium
generating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024556148A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025509969A5 (enExample
Inventor
ゲイリー デクレッセンゾ，
マーティン テレスク，
Original Assignee
バイオメッド バレー ディスカバリーズ，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオメッド バレー ディスカバリーズ，インコーポレイティド filed Critical バイオメッド バレー ディスカバリーズ，インコーポレイティド
Publication of JP2025509969A publication Critical patent/JP2025509969A/ja
Publication of JP2025509969A5 publication Critical patent/JP2025509969A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024556148A 2022-03-24 2023-03-24 Ｅｒｋのピロール阻害剤の重水素化アナログ、その合成およびその中間体 Pending JP2025509969A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263323221P 2022-03-24 2022-03-24
US63/323,221 2022-03-24
PCT/US2023/064908 WO2023183905A2 (en) 2022-03-24 2023-03-24 Deuterated analogs of pyrrole inhibitors of erk, synthesis thereof and intermediates thereto

Publications (2)

Publication Number Publication Date
JP2025509969A true JP2025509969A (ja) 2025-04-11
JP2025509969A5 JP2025509969A5 (enExample) 2026-04-01

Family

ID=88102044

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024556148A Pending JP2025509969A (ja) 2022-03-24 2023-03-24 Ｅｒｋのピロール阻害剤の重水素化アナログ、その合成およびその中間体

Country Status (10)

Country Link
US (1) US20250026733A1 (enExample)
EP (1) EP4499623A2 (enExample)
JP (1) JP2025509969A (enExample)
CN (1) CN119212985A (enExample)
AU (1) AU2023238106A1 (enExample)
CA (1) CA3245978A1 (enExample)
IL (1) IL315702A (enExample)
MX (1) MX2024011415A (enExample)
TW (1) TW202400572A (enExample)
WO (1) WO2023183905A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025250391A1 (en) * 2024-05-28 2025-12-04 Biomed Valley Discoveries, Inc. Compositions and methods for solid forms of ulixertinib

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA84930C2 (ru) * 2004-05-14 2008-12-10 Вертекс Фармасьютикалс Инкорпорейтед Пиррольные соединения как ингибиторы протеинкиназ erk, их синтез и соответствующие промежуточные соединения
US9227969B2 (en) * 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
HK1244274A1 (zh) * 2015-01-30 2018-08-03 生物医学谷探索股份有限公司 C21h22ci2n4o2的晶型

Also Published As

Publication number Publication date
IL315702A (en) 2024-11-01
CA3245978A1 (en) 2023-09-28
WO2023183905A3 (en) 2023-10-26
TW202400572A (zh) 2024-01-01
US20250026733A1 (en) 2025-01-23
WO2023183905A2 (en) 2023-09-28
EP4499623A2 (en) 2025-02-05
AU2023238106A1 (en) 2024-09-26
CN119212985A (zh) 2024-12-27
MX2024011415A (es) 2024-09-24

Similar Documents

Publication Publication Date Title
JP2022071072A (ja) （ｓ）－７－（１－アクリロイルピペリジン－４－イル）－２－（４－フェノキシフェニル）－４，５，６，７－テトラ－ヒドロピラゾロ［１，５－ａ］ピリミジン－３－カルボキサミドの結晶形、その調製、及びその使用
TWI405761B (zh) 適合作為傑納斯激酶（ｊａｎｕｓ ｋｉｎａｓｅ）抑制劑之氮雜吲哚
AU2013274030B2 (en) Deuterated derivatives of ruxolitinib
DE602004011330T2 (de) Imidazo- und thiazolopyridine als jak3-kinase-inhibitoren
CN102596960B (zh) 3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的羟基衍生物、酮基衍生物和葡糖苷酸衍生物
JP2023030076A (ja) Ｆｘｒアゴニストの固体形態
CN104507946A (zh) 氘代依鲁替尼
SK5912003A3 (en) Novel pyridine-substituted pyrazolopyridine derivatives
TW200520758A (en) Novel pharmaceuticals
KR20100050466A (ko) 섬유증 저해제로서의 치환된 ｎ-아릴 피리디논
CN102459270A (zh) Janus激酶3的哌啶抑制剂
US11534434B2 (en) Xanomeline derivatives and methods for treating neurological disorders
EP3126331A1 (en) Oxindole inhibitors of tyrosine kinase
FR2941948A1 (fr) Derives d'azaindoles en tant qu'inhibiteur des proteines kinases abl et src
WO2018133875A1 (zh) Jak酶抑制剂及其制备方法和用途
US20250026733A1 (en) Deuterated analogs of pyrole inhibitors of erk, synthesis thereof and intermediates thereto
JP5726321B2 (ja) オキサゾロ［５，４−ｂ］ピリジン−５−イル化合物および癌治療へのその使用
HK40118078A (zh) Erk的吡咯抑制剂的氘代类似物、其合成及其中间体
JP7607799B2 (ja) ６員芳香族ヘテロ尿素環の誘導体及びその使用
WO2015120393A1 (en) Substituted triazolobenzodiazepines
CN119053573A (zh) 氘代咪唑克生及其使用方法
WO2014028914A1 (en) Deuterated icotinib derivatives
CN111630048B (zh) 脒类和胍类衍生物、其制备方法及其在医药上的应用
CN107964012B (zh) 作为parp抑制剂的化合物及其用途
TWI692476B (zh) 環丁基-咪唑啶酮化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260324

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260324